Stock BVNRY BAVARIAN NORDIC A/S
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Bavarian Nordic A/S OTC Markets

Equities

BVNRY

US0717711099

Delayed OTC Markets
Other stock markets
 13:42:25 2024-06-10 EDT 		5-day change 1st Jan Change
8.51 USD -1.85% Intraday chart for Bavarian Nordic A/S -4.61% -2.69%
05-31 Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine MT
05-30 Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine
Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children
Bavarian Nordic A/S and Coalition for Epidemic Preparedness Innovations Partners to Advance Mpox Vaccination in Africa
Bavarian Nordic’s Medical Chief to Step Down by May-end
Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer
Bavarian Nordic A/S commences an Equity Buyback Plan, under the authorization approved on April 16, 2024.
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024
Bavarian Nordic A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
Bavarian Nordic Books EUR65 Million Order for Smallpox Vaccine
Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve
Bavarian Nordic Starts US Rolling Submission Process for Chikungunya Vaccine Candidate
Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate
OPINIONES DE LOS ANALISTAS DEL DÍA : Acciona, LVMH, Endesa, Viscofan, Easyjet, Repsol, Unibail, Sika, Rio Tinto, Unicredit, ASML...
Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023
Bavarian Nordic A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Bavarian Nordic Receives Accelerated Assessment Status for Chikungunya Vaccine
Bavarian Nordic A/S Announces Accelerated Assessment for the Upcoming Marketing Authorisation Application for CHIKV VLP
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BAVA Stock
  4. BVNRY Stock
  5. News Bavarian Nordic A/S
  6. Other languages